secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-07-26T23:59:59+00:00
Accession:  0001641489-24-000057
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on vTv Therapeutics' cadisegliatin Phase 3 trial for type 1 diabetes
--------------------------------------------------------------------------------

- FDA clinical hold based on unresolved chromatographic signal in cadisegliatin ADME study.
- FDA requires a single in vitro study to characterize signal before program can resume.
- No patients had been dosed in CATT1 Phase 3 trial at time of hold; no prior safety issues.
- vTv is working with FDA to resolve hold and resume enrollment as quickly as possible.
- Cadisegliatin is an oral glucokinase activator; over 500 subjects dosed to date with favorable safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000057/0001641489-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000057/vtvt-20240726.htm
  HTML page:      https://secwatch.observer/filing/0001641489-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer